Combined Thiazolidinedione-Insulin Therapy

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Drug Safety

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00002018-200427120-00002PMID 15366973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pioglitazone

  2012cited by this paper
• Troglitazone

  2012cited by this paper
• Rosiglitazone

  2012cited by this paper
• Current Management Strategies for Coexisting Diabetes Mellitus and Obesity

  2012cited by this paper
• Metabolic and Additional Vascular Effects of Thiazolidinediones

  2012cited by this paper
• Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double‐blind, multicentre, randomized study

  2006cited by this paper
• Pioglitazone: cardiovascular effects in prediabetic patients.

  2006cited by this paper
• Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?

  2004cited by this paper
• Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione.

  2004cited by this paper
• Rosiglitazone and Heart Failure: Long-Term Vigilance

  2004cited by this paper
• Thiazolidinedione-Induced Congestive Heart Failure

  2004cited by this paper
• Higher incidence of new-onset diabetes in patients with heart failure.

  2003cited by this paper
• Pathophysiological implications of insulin resistance on vascular endothelial function

  2003cited by this paper
• Do thiazolidinediones cause congestive heart failure?

  2003cited by this paper
• Hypoglycemia in diabetes.

  2003cited by this paper
• Heart failure: the frequent, forgotten, and often fatal complication of diabetes.

  2003cited by this paper
• Unilateral edema due to a thiazolidinedione.

  2003cited by this paper
• Influence of diabetes mellitus on heart failure risk and outcome

  2003cited by this paper
• Thiazolidinedione-associated congestive heart failure and pulmonary edema.

  2003cited by this paper
• Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Functional class in patients with heart failure is associated with the development of diabetes.

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity.

  2003cited by this paper
• Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

  2003cited by this paper
• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  2003cited by this paper
• Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.

  2003cited by this paper
• PATHOPHYSIOLOGY OF TYPE 2 DIABETES

  2003cited by this paper
• Is the tolerability of long-term thiazolidinedione therapy overstated?

  2003cited by this paper
• ROSIGLITAZONE: POTENTIAL BENEFICIAL IMPACT ON CARDIOVASCULAR DISEASE

  2003cited by this paper
• Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.

  2003cited by this paper
• Metformin and thiazolidinedione use in Medicare patients with heart failure.

  2003cited by this paper
• Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone.

  2003cited by this paper
• PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?

  2003cited by this paper
• Thiazolidinedione Safety and Efficacy in Ambulatory Patients Receiving Hemodialysis

  2003cited by this paper
• Incidence of Idiopathic Acute Liver Failure and Hospitalized Liver Injury in Patients Treated With Troglitazone

  2003cited by this paper
• Cardioprotection with pioglitazone is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts–comparison of the effects of pioglitazone and metformin

  2003cited by this paper
• New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.

  2003cited by this paper
• Glitazones and heart failure: critical appraisal for the clinician.

  2003cited by this paper
• Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability

  2003cited by this paper
• The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

  2003cited by this paper
• Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.

  2003cited by this paper
• Benefits of combination therapy of insulin and oral hypoglycemic agents.

  2003cited by this paper
• Glitazones: clinical effects and molecular mechanisms

  2002cited by this paper
• Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists.

  2002cited by this paper
• Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

  2002cited by this paper
• The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

  2002cited by this paper
• Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

  2002cited by this paper
• Troglitazone Improves Cardiac Function in Patients with Congestive Heart Failure

  2002cited by this paper
• Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes

  2002cited by this paper
• Thiazolidinedione‐Induced Edema

  2002cited by this paper
• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  2002cited by this paper
• EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY

  2002cited by this paper
• Are all glitazones the same?

  2002cited by this paper
• Obesity and liver disease.

  2002cited by this paper
• Thiazolidinediones: A Review of Their Benefits and Risks

  2002cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cited by this paper
• Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.

  2002cited by this paper
• [Glitazones and weight gain].

  2002cited by this paper
• A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

  2002cited by this paper
• Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

  2002cited by this paper
• Glitazones et prise de poids

  2002cited by this paper
• Regional differences in the response of human pre-adipocytes to PPARγ and RXRα agonists

  2002cited by this paper
• The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.

  2001cited by this paper
• Hepatotoxicity with Thiazolidinediones

  2001cited by this paper
• A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.

  2001cited by this paper
• Peroxisome Proliferator-Activated Receptor &ggr; Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes

  2001cited by this paper
• Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.

  2001cited by this paper
• Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.

  2001cited by this paper
• Lessons from the glitazones: a story of drug development.

  2001cited by this paper
• Oświadczenie w sprawie konfliktu interesów

  2001cited by this paper
• Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.

  2001cited by this paper
• PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE

  2001cited by this paper
• Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes.

  2001cited by this paper
• Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.

  2001cited by this paper
• Combination therapies with insulin in type 2 diabetes.

  2001cited by this paper
• New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

  2001cited by this paper
• Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.

  2001cited by this paper
• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma and metabolic disease.

  2001cited by this paper
• Nonhypoglycemic Effects of Thiazolidinediones

  2001cited by this paper
• Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.

  2001cited by this paper
• Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.

  2001cited by this paper
• Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions.

  2001cited by this paper
• Pulmonary Edema Associated with Rosiglitazone and Troglitazone

  2001cited by this paper
• In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-&ggr; Agonist Rosiglitazone

  2001cited by this paper
• Insulin resistance and cardiovascular disease.

  2001cited by this paper
• The Management of Obesity and Related Disorders

  2001cited by this paper
• Troglitazone and related compounds: therapeutic potential beyond diabetes.

  2000cited by this paper
• Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.

  2000cited by this paper
• Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?

  2000cited by this paper
• Long-Term Prevention of Bone Loss

  2000cited by this paper
• Peroxisome proliferator‐activated receptors in the cardiovascular system

  2000cited by this paper
• Efficacy of troglitazone on body fat distribution in type 2 diabetes.

  2000cited by this paper
• Optimising Therapy for Insulin-Treated Type 2 Diabetes Mellitus

  2000cited by this paper
• Heart failure and glucose abnormalities: an increasing combination with poor functional capacity and outcome.

  2000cited by this paper
• Combining insulin and oral agents.

  2000cited by this paper
• Thiazolidinedione hepatotoxicity: a class effect?

  2000cited by this paper
• The perils of portliness: causes and consequences of visceral adiposity.

  2000cited by this paper
• Troglitazone-induced pulmonary edema.

  2000cited by this paper

• Comparison of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter protein-2 inhibitors on treating metabolic dysfunction-associated steatotic liver disease or metabolic dysfunction-associated steatohepatitis: systematic review and network meta-analysis of randomised controlled

  2024cites this paper
• Approach to the Patient with Non-cardiac Leg Swelling.

  2023cites this paper
• Practical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus

  2022cites this paper
• Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies

  2022cites this paper
• From an Apple to a Pear: Moving Fat around for Reversing Insulin Resistance

  2022cites this paper
• Careful use to minimize adverse events of oral antidiabetic medications in the elderly

  2021cites this paper
• Which antidiabetic drug indications are recommended for geriatric DM patients?

  2021cites this paper
• The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis

  2020cites this paper
• Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes

  2020cites this paper
• Heart failure in diabetes mellitus: an updated review.

  2020cites this paper
• Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation

  2020cites this paper
• BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion

  2019cites this paper
• Pharmacotherapy of type 2 diabetes: An update.

  2018cites this paper
• Supercritical Fluid-Assisted Decoration of Nanoparticles on Porous Microcontainers for Codelivery of Therapeutics and Inhalation Therapy of Diabetes.

  2018cites this paper
• Vignette therapeutique de l'etudiant. Quel medicament antidiabetique choisir chez un patient diabetique de type 2 avec insuffisance cardiaque ?

  2017cites this paper
• Pharmacotherapy of ‘treatment resistant’ type 2 diabetes

  2017cites this paper
• Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin

  2017cites this paper
• Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: Novel move towards combination therapies.

  2017cites this paper
• Palmitate-induced insulin resistance is attenuated by Pioglitazone and EGCG through reducing the gluconeogenic key enzymes expression in HepG2 cells

  2017cites this paper
• Practical combination therapy based on pathophysiology of type 2 diabetes

  2016cites this paper
• Antiallergic Function of KR62980, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in a Mouse Allergic Rhinitis Model

  2015cites this paper
• Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

  2015cites this paper
• The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.

  2014cites this paper
• Peroxisome proliferator-activated receptor activating hypoglycemic effect of Gardenia jasminoides Ellis aqueous extract and improvement of insulin sensitivity in steroid induced insulin resistant rats

  2014cites this paper
• Role of PPARs in inflammatory processes associated with metabolic syndrome (Review).

  2013cites this paper
• The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus

  2013cites this paper
• Dual Peroxisome Proliferator-Activated Receptor-α/γ Agonists

  2012cites this paper
• Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes

  2012cites this paper
• Outcomes and lessons from the PROactive study.

  2012cites this paper
• Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.

  2012cites this paper
• Suspension de la commercialisation de la sibutramine et de la rosiglitazone en Europe

  2010cites this paper
• Respuesta del Dr. Manuel Delgado Gómez

  2010cites this paper
• Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.

  2010cites this paper
• Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation.

  2010cites this paper
• Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator‐activated receptor γ co‐activator‐1α protein

  2010cites this paper
• The Continuation of Oral Medications with the Initiation of Insulin Therapy in Type 2 Diabetes: A Review of the Evidence

  2010cites this paper
• Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin

  2010cites this paper
• Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities

  2009cites this paper
• Massive bilateral pleural effusion associated with use of pioglitazone.

  2008cites this paper
• Cardiovascular risk of rosiglitazone: another perspective

  2008cites this paper
• Retrospective Analysis of Rosiglitazone and Macular Oedema in Patients with Type 2 Diabetes Mellitus

  2008cites this paper
• Drug Class Review: Thiazolidinediones: Final Report Update 1

  2008cites this paper
• Uncovering Imperative Interventions in Prediabetes and Type 2 Diabetes

  2008cites this paper
• The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer

  2008cites this paper
• Late-Onset Rosiglitazone-Associated Acute Liver Failure in a Patient with Hodgkin's Lymphoma

  2008cites this paper
• Rosiglitazone-induced anasarca without heart failure: capillary leakage?

  2008cites this paper
• Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes

  2008cites this paper
• Pharmacokinetic Interactions with Thiazolidinediones

  2007cites this paper
• Insulin, other hypoglycemic drugs, and glucagon

  2007cites this paper
• [Effects of Astragalus polysaccharides on proliferation and differentiation of 3T3-L1 preadipocytes].

  2007cites this paper
• Combined Pioglitazone-Insulin Use: Analysis from the Pioglitazone Prescription-Event Monitoring Study

  2007cites this paper
• Glitazones et insuffisance cardiaque : résultats des études PROactive, ADOPT, DREAM et RECORD

  2007cites this paper
• Soy Protein and Isoflavones Influence Adiposity and Development of Metabolic Syndrome in the Obese Male ZDF Rat

  2007cites this paper
• Drug-Induced Cardiovascular Disorders

  2007cites this paper
• Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy

  2007cites this paper
• Dioscorea as the principal herb of Die-Huang-Wan, a widely used herbal mixture in China, for improvement of insulin resistance in fructose-rich chow-fed rats.

  2007influential citation
• The next generation of PPAR drugs: do we have the tools to find them?

  2007cites this paper
• Le traitement du diabète de type 2: entre insulinosensibilisateurs et insulinosécrétagogues

  2007cites this paper
• Insuffisance cardiaque et diabète de type 2: une relation à double sens

  2007cites this paper
• Oral Antidiabetic Drugs

  2006cites this paper
• The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin

  2006cites this paper
• Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double‐blind, multicentre, randomized study

  2006cites this paper
• Le syndrome metabolique: physiopathologie et traitement

  2006cites this paper
• THE EFFECTS OF FLAXSEED ON THE GLUCOSE PROFILE IN NATIVE AMERICAN POSTMENOPAUSAL WOMEN

  2006cites this paper
• Thiazolidinedione induced gross scrotal oedema

  2006cites this paper
• Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.

  2006cites this paper
• Diabete sucre et decompensation cardiaque: specificites ethiopathogeniques et therapeutiques.

  2006cites this paper
• PPARgamma activity in the vessel wall: anti-atherogenic properties.

  2006cites this paper
• Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease

  2006cites this paper
• P eroxisome Proliferator-Activated Receptors at the rossroads of Obesity , Diabetes , and Cardiovascular Disease

  2006cites this paper
• Drug-induced weight gain

  2005cites this paper
• Increase of insulin sensitivity by stevioside in fructose-rich chow-fed rats.

  2005cites this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.

  2005cites this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents

  2005cites this paper